Related Experiment Videos
Basal Ganglia calcification in mitochondrial disorders
Josef Finsterer1, Wolfgang Kopsa
1duarte@aonmail.at
Metabolic Brain Disease
|September 17, 2005
Summary
Basal ganglia calcification (BGC) affects one-sixth of mitochondriopathy patients, often presenting with central nervous system (CNS) issues and multisystem disease. This study quantifies BGC frequency and associated abnormalities in a large cohort.
Area of Science:
- Neurology
- Radiology
- Genetics
Background:
- Basal ganglia calcification (BGC) is a known, yet infrequently studied, feature of mitochondriopathy.
- Understanding the prevalence and clinical significance of BGC in a larger patient cohort is crucial.
Purpose of the Study:
- To determine the frequency of BGC in patients with mitochondriopathy.
- To characterize the clinical and imaging abnormalities of the central nervous system (CNS) and other organ systems in these patients.
Main Methods:
- Retrospective review of cerebral CT scans from mitochondriopathy patients over 10 years.
- Analysis of clinical data, additional imaging findings (CT and MRI), and non-CNS system involvement.
Main Results:
- BGC was identified in 36 patients (one-sixth of the cohort) with mitochondriopathy.
- Common CNS manifestations included epilepsy, Parkinsonism, and dementia.
- Multisystem involvement was frequent, affecting the CNS, endocrine, peripheral nervous, and cardiac systems.
Conclusions:
- BGC is a relatively common finding in patients with mitochondriopathy.
- BGC is associated with a high frequency of CNS abnormalities and multisystemic disease, underscoring its clinical relevance.